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Abstract MicroRNAs (miRNAs) are recently discovered
posttranscriptional regulators of gene expression that have
become a cause célèbre. There are currently more than 600
miRNAs identified in humans that are estimated to regulate
about one third of all messenger RNA (mRNA). Because
miRNA levels were found widely deregulated in diseases,
they have been implicated in the underlying pathogenesis.
In addition, the changes in their expression patterns are
proving to be reliable diagnostic and prognostic measures.
But the specific mRNA targets and, hence, function of each
miRNA is still work-in-progress. This information would be
necessary before fully exploiting miRNA for therapeutic
purposes. In this review we will discuss why miRNAs are
considered major posttranscriptional regulators and how they
impact gene expression and cell function during cardiac
hypertrophy and failure. In addition, we will highlight their
potential for therapeutic targeting.
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MicroRNA and the Impact of Posttranscriptional
Regulation on Gene Expression
MicroRNAs (miRNAs) are short oligoribonucleotides that
posttranscriptionally regulate gene expression. Guided by
sequence complementarity, they specifically target messenger
RNA (mRNA) and inhibit translation or induce degradation.
Posttranscriptional regulatory mechanisms appear to play a
fundamental role in determining a gene’s translational output.
This is deduced from the simple fact that relative mRNA
levels do not reflect the corresponding cellular protein levels
[1]. A study by Beyer et al. confirmed weak or no correlation
between mRNA and protein abundance for the whole cell
[2]. Similar results were obtained for measurements of
different cellular compartments. But, interestingly, a more
positive correlation emerged when they grouped functionally
related genes. In agreement, the decay rates of mRNA for
genes that are functionally related were similar [3]. This
suggests that functionally related genes are posttanscription-
ally regulated by a common denominator.
According to our current knowledge of miRNAs and their
targets, an individual miRNA has the potential to regulate a
set of specific genes involved in a common cellular function.
For example, we observed that miR-1 targets an array of
growth-related genes that have been previously implicated in
the development of cardiac hypertrophy, which include Ras
GTPase-activating protein, cyclin-dependent kinase 9,
endothelin, fibronectin, Ras homologue enriched in brain,
eukaryotic initiation factor 4E, JunD, quaking, insulin-like
growth factor, and Rap1. In accordance, upon induction of
cardiac hypertrophic growth, miR-1 is downregulated and
translation of those targets is uninhibited [4]. Similarly,
when John et al. [5] analyzed individual miRNA for gene
ontology they observed that some favored certain terms. For
example, miR-208 targets were biased toward “transcription
factor,” while miR-105 had a preponderance of “small
GTPase-mediated signal transduction” [5]. Thus, miRNAs
offer a mechanism whereby functionally related genes can
have similar expression patterns and decay rates.
Farh et al. reported that predicted mRNA targets of
tissue-enriched miRNAs were lower in the corresponding
tissue [6]. Moreover, those targets were initially high in
those tissues before the increase in the targeting miRNA,
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albeit they were not completely eliminated. This suggested
that miRNAs are involved in both mRNA decay, as well as,
translational repression. In agreement, Lim et al. showed
that by expressing the muscle-specific miR-1 or the brain-
specific miR-124 in HeLa cells the mRNA expression pattern
shifted towards the corresponding tissue [7]. These data
support the view that posttranscriptional regulation by
miRNA defines tissue function and fate.
Evidence that miRNA are Major Regulators of Gene
Expression and Function in the Heart
Similar to other pathologies, cardiac hypertrophy and failure
are characterized by an overall modification of the gene
expression profile within the cardiac myocytes. During
compensatory hypertrophy this profile appears, to a great
extent, to recapitulate that of the neonatal heart. This is in
concordance with the fact that the latter is also in a phase of
hypertrophic growth [8]. Conceivably, this switch is triggered
by transcriptional and/or posttranscriptional events. If we
assume the position that miRNA play a major role in the
reprogramming of gene expression during hypertrophy we,
thus, are predicting that miRNAs expression will, in parallel
with its targets, revert to the neonatal pattern. We tested this
hypothesis, and as seen in Fig. 1, the majority of miRNAs
that were differentially deregulated in pressure overload
hypertrophy vs. sham hearts in a mouse model reverted to
their neonatal vs. adult pattern. These results provided us
with the first clue that miRNA play a major role in gene
regulation during cardiac hypertrophy.
MiR-1 is one of the better-characterized miRNA, which
constitutes ∼45% of total miRNA in the heart. First identified
as a muscle-enriched miRNA [9], its expression is detected as
early as embryonic day (E) 8.5 in the mouse heart, and
increases with the progression of differentiation [10]. In
Drosophila, a DmiR-1KO mutant dies as a small second in-
star larvae, 2–7 days after hatching, from apparent paralysis
[11]. Similarly, disrupting miR-1–2 in a homozygous mouse
model results in ventricular septal defects and lethality
between E15.5 to immediate postnatal [12]. Recently, a few
reports have also implicated miR-1 in development of cardiac
hypertrophy [4, 13] and arrhythmias [14]. This further proves
that miRNA are major regulators of gene expression that
govern heart development and function.
MiRNA Mediate Specific Translation Regulation
“On Demand”
Although, there are many known posttranscriptional regu-
lators of gene expression, there are none that afford such a
global and specific effect as miRNAs, which is why they
have attracted much attention. MiRNAs impact protein
expression in a way similar to a transcription factor, that is
by effecting a specific increase or decrease in the translation
product. For many one and for one many, characterizes how
both these molecules recognize their targets, while fundamen-
tally diverging in the underlying mechanism of function.
Whereas transcription factors regulate mRNA synthesis of a
gene through binding its promoter, miRNA directly bind to a
specific sequence within the 3’UTR of an mRNA and inhibit
protein translation and/or induced mRNA degradation
(Fig. 2). In general, when a miRNA is attached, translation
is off, and vice versa, thus, functioning as a molecular switch.
What we can extrapolate from this comparison is that
miRNAs can accomplish their function in a more direct
and, thus, a more rapid fashion, relative to transcription
factors. Transcriptional regulation not only involves mRNA
synthesis, but most often requires DNA remodeling as well.
Additionally, in the event that inhibition of protein synthesis
is the objective, the effect would be delayed by as long as the
decay time of the preexisting mRNA. Overall, transcriptional
regulation is evidently more energy- and time-consuming
relative to miRNA regulation. This leads us to propose that
deregulation of miRNAwould allow the cell to respond to an
Fig. 1 Comparison between the differentially expressed miRNA in
transverse aortic constriction-induced hypertrophy and physiological
hypertrophy of the neonatal heart. A density heatmap comparing the
distribution of the log 2 values of miRNA differentially expressed in
the hearts of mice subjected to TAC/sham (x-axis) versus those of
neonatal/adult hearts (y-axis). Red is a region containing data points
more than expected; blue is a region containing data points less than
expected (scale, right). The heatmap shows a majority of miRNA that
are similarly downregulated (red, lower left quadrant) or upregulated
(red, upper right quadrant) in both the hypertrophy/sham and
neonatal/adult hearts. The red in the upper left quadrant represents
miRNA that were upregulated during hypertrophy but were lower in
the neonatal vs. adult
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incoming signal without delay. One caveat to this theory,
though, is that miRNA levels themselves have to be altered
before eliciting a change in a gene’s translation. It has been
generally assumed that miRNA are mainly regulated by
transcriptional events, which would negate the possibility of
their immediate response to a cell signal. Recently, though,
data has been accumulating regarding posttranscriptional
regulation of miRNA, as will be discussed below.
MiRNA as Immediate-Early Responders to Cellular
Stimuli
Our recent data demonstrate that some miRNA are deregu-
lated relatively early in response to a stimulus, which provides
a new prospect for therapeutics. We have reported that the
heart responds to pressure overload by immediately down-
regulating miR-1, prior to any obvious change in gene
expression, heart size, or function. Downregulation of miR-1
implies that the translation of its targets will be uninhibited.
Although we have not ruled out transcriptional regulation of
miR-1, we have discovered that the RNA binding and
hydrolyzing protein Ras-GAP SH3-binding protein (G3BP)
binds to the miR-1 precursor through a conserved consensus
sequence. The significance of this finding was tested by
measuring the effect of overexpression or knockout of G3BP
on miR-1 in myocytes, the results of which showed down-
regulation or upregulation of miR-1, respectively (D. Sayed
and M. Abdellatif, unpublished data). G3BP itself is regulated
by phosphorylation. The results provide a mechanism
whereby miR-1 is rapidly downregulated, while circum-
venting a need for transcriptional regulation. This intimates
that miR-1, has the capacity to function as one of the first
responders to hypertrophic stimuli, and is a cause rather than
an effect of cardiac hypertrophy. Consequently, we speculated
that miR-1 target genes must play a fundamental role in
initiating cardiac hypertrophy. In accordance, we identified
many predicted targets that fit that description and have
confirmed a few byWestern blotting. Some of those genes are
listed above, but the most intriguing is eIF4E. EIF4e is
upregulated during cardiac hypertrophy in a mouse model,
which is inhibited if downregulation of miR-1 is normalized
by an exogenous construct, as seen in cultured rat neonatal
myocytes (Fig. 3). Since eIF4E is the limiting factor in
translation initiation of all capped mRNA, it was not
surprising that all luciferase reporter constructs, with or
without the miR-1 target site in the 3’UTR, were dramatically
inhibited in the presence of excess miR-1, making it difficult
to distinguish its direct from indirect targets (D. Sayed and M.
Abdellatif, unpublished data). EIF4e is, conceivably, the
Achilles heel of cardiac hypertrophy, by reason that it is the
limiting factor in protein synthesis, which elicits an increase in
cell size that defines hypertrophy. This further emphasizes a
role for miR-1 in initiating cardiac hypertrophy.
There is accumulating evidence that miRNAs are
regulated by posttranscriptional mechanisms. First demon-
Fig. 2 Comparison of posttranscriptional regulation by miRNA vs.
transcriptional regulation of gene expression. 1 Levels of miRNA are
posttranscriptionally regulated. 2 This results in a miRNA attachment to
the 3’UTR of a gene and inhibition of translation or mRNA degradation,
or its detachment and activation of translation, thus, acting as a
molecular switch that could result in an immediate early effect in
response to an incoming signal. On the other hand, transcriptional
regulation requires: 1 DNA remodeling; 2 attachment or detachment of
the transcription factor; and 3 inhibition or activation of RNA synthesis,
before an effect on 4 protein levels is observed, thus, resulting in a
relatively late response to an incoming signal
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strated by Thomson et al, where they showed that there is
little or no correlation between primary and mature miRNA,
plausibly due to selective processing by Drosha in both
normal and cancer tissue [15]. More recently, it was
discovered that Lin-28 selectively binds to and inhibits
the processing of primary let-7 miRNA [16, 17]. Further-
more, miRNAs are subject to posttranscriptional editing,
where adenosine is converted to inosine. Luciano et al were
the first to notice that premature miR-22 is edited at multiple
sites [18]. It is estimated that ∼6% of human miRNA are
edited [19]. Importantly, some of the edited sites are within
the ‘seed’ region and result in reassignment of targets [20].
This demonstrates the extensiveness of posttranscriptional
regulation of miRNA as a mechanism that would elicit a
rapid change in their level or targeting capacity in response
to a cell signal.
miRNA vs. mRNA for Therapeutic Targeting
As well established, a single protein does not independently
fulfill a cellular function, but is part of a consortium of
genes with distinct, but also overlapping, roles that ensure
perpetuation of function. For example, we would argue that
while upregulation of eIF4E by way of downregulation of
miR-1 is an essential step in initiating protein synthesis, other
targets are necessary for maximal protein synthesis. For
example, RasGAP is required for activating RNA polymerase
II and subsequently mRNA synthesis [21]. Since, an increase
in protein synthesis would be limited by mRNA availability,
it becomes clear why upregulation of RasGAP is equally
important for maximizing protein synthesis. Accordingly, we
predict that other growth-related targets of miR-1 collaborate
with eIF4E to achieve complete hypertrophic growth.
From that prospective, it would be more effective to inhibit
hypertrophy by normalizing miR-1 versus any single mRNA
target. Similarly, it was more effective to inhibit proliferation
by simultaneously rather than individually inhibiting the cell
cycle-related miR-16 targets [22]. This demonstrates that
miRNA have the potential to serve as more powerful
therapeutic targets than would individual genes.
Although we have a wealth of information regarding the
differentially expressed miRNA in cardiac hypertrophy and
failure [4, 23–27], we know little about their targets,
functions, or cause–effect relationship. Besides miR-1 that
we have discussed above, the downregulation of miR-133a
was proven sufficient for induction of hypertrophy [24].
Interestingly, both these miRNAs are muscle-enriched. On
the other hand, the mature form of cardiac-specific miR-208
remains unaltered in either human failing hearts or during
cardiac hypertrophy in wild type mice [28], thus, should
have no consequence on its targets’ expression or thera-
peutic value. Another potential therapeutic target is miR-
195, which is upregulated during cardiac hypertrophy and
induces cardiac failure in a transgenic mouse model [23]. It
is worth noting that miR-195, among a few others, deviated
from the characteristic rewind to the neonatal pattern seen
during hypertrophy. These few miRNA are represented in
the upper left quadrant of the heatmap in Fig. 1. The changes
in these miRNA might distinguish pathological from
physiological growth. Identifying the targets and functions
of these miRNA would help validate this idea and their
potential for therapeutic targeting.
On the other hand, miR-21 plays a positive role during
growth by inhibiting apoptosis as demonstrated in cancer-
ous cells [29, 30, 31] and inducing cell invasion, but not
proliferation, through inhibition of programmed cell death 4
(Pdcd4) [32]. In human colorectal cancer the levels of miR-
21 positively correlated with the development of metastasis
but not tumor size [33]. In the heart, we have shown that
miR-21 is upregulated in parallel with the increase in
cardiac mass, but starts declining upon the onset of cardiac
dysfunction and dilatation [34]. Transgenic mouse lines
overexpressing miR-21, ∼10 and 30-fold in excess of
endogenous, do not exhibit an overt phenotype, where
cardiac size, histology, and all functional parameters are
normal (D. Sayed and M. Abdellatif, unpublished results).
But upon closer investigation, we determined that miR-21
induced lateralization of connexin43 (Cx43) that is other-
wise strictly localized to the intercalated discs (Fig. 4). This
is similar to the redistribution of Cx43 seen in peri-infarct
zones [35] and during adaptive hypertrophy [36, 37],
thought to enhance conduction and decrease arrhythmias.
At the onset of cardiac failure, though, this effect is reversed,
Fig. 3 Eukaryotic initiation factor 4E (eIF4E) is upregulated during
cardiac myocyte hypertrophy and is inhibited by miR-1. Left panels
Western blot analysis of protein extracted from pressure overloaded
(TAC), hypertrophied, mouse hearts (where marked by a + sign above
the Western blot lane), or a sham control (unmarked lane), using an
eIF4E antibody (upper panel) or a glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody for an internal control (lower
panel). Right panels rat cardiac myocytes were cultured in fetal bovine
serum (FBS)-free medium. Cells were then stimulated with 10% FBS
for 24 h to induce hypertrophy, in the absence or presence of excess
miR-1 that was delivered by recombinant adenovirus (where marked
by + signs above the Western blot lanes). Total protein was extracted
and analyzed by Western blotting as indicated above
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as is the upregulation of miR-21. Thus, this would be a
good example of a miRNA that would benefit from gene
replacement therapy during cardiac failure.
Tools for Modulating miRNA Levels
MiRNA can be either upregulated or downregulated during
a disease and will accordingly require different approaches
for normalizing its levels. In this section we describe the
available tools and techniques that have been developed for
those purposes.
MiRNA Specific Antisense oligonucleotides Antisense oligo-
deoxynucleotides are widely used as a tool for targeting and
inhibiting mRNA translation. Various backbone and 2′-sugar
modifications were introduced to enhance their stability and
cellular uptake. For example, phosphorothioate modifications,
where a nonbridging oxygen within the internucleoside bond
is replaced by a sulfur atom, render oligonucleotides more
resistant to nuclease activity, thus, prolonging their half-life
[38]. Moreover, such modified oligonucleotides were found
to be highly bound to plasma proteins, which delayed their
urinary excretion [39]. It should be noted, though, that the
phosphorothioate-modified linkers decreased the affinity to
the complementary sequence. Also, it was found that 2′-
O-sugar modifications are essential for an oligonucleotide’s
effectiveness, where those uniformly modified with 2′-
O-methoxyethyl (2′-O-MOE) were much more effective than
those with 2′-O-methyl (2′-O-Me) [40]. But at high doses
only 2′-O-Me induced significant toxicity in cultured Hela
cells. These oligonucleotides appear to enter the cells via
scavenger receptors and when injected in vivo become highly
concentrated in the liver, kidneys, and bone marrow [41].
Different versions of modified and cholesterol conjugat-
ed antisense miRNAs were applied in vivo with great
success. Hutvagner et al. were the first to report that 2′-
O-methyl oligonucleotides successfully inhibited miRNA
let-7 function in Drosophila [42], while Esau et al. observed
enhanced inhibition of liver miR-122 in mice by using 2′-
O-MOE phosphorothioate modified oligodeoxynucleotides
[43]. In the latter case, the minimum effective dose tested
for lowering cholesterol was 12.5 mg/kg (2×/week for
4 weeks), although, miR-122 was further reduced at higher
doses. Similarly, injection of 2′-O-methyl, phosphoro-
thioate, 5′-cholesterol-conjugated antisense miR-122 mod-
ified oligonucleotides “antagomirs”, inhibited miR-122 in
the liver [44]. In addition, the use of unusually high doses
(3×80 mg/kg) of the antagomirs successfully knocked
down miR-16 in other organs including lung, kidney, heart,
intestine, fat, skin, bone marrow, muscle, ovaries, and
adrenals. The utility of antagomirs was further confirmed in
the heart by knockdown of miR-133a, which demonstrated
its role in inducing hypertrophy [24]. These antagomirs
appear to function by binding to the mature miRNA within
the cytoplasmic compartment, but not in P-bodies, and
induces its degradation [45].
MiRNA Sponges As the name implies, this construct is
designed to absorb cellular miRNA, but unlike the antisense
oligonucleotides, it does not induce significant degradation
of the target [46]. There are 2 different designs, one where
multiple specific miRNA complimentary sites are incorpo-
rated in the 3’UTR of a gene, such as green florescence
Fig. 4 Lateralization of Cx43 in miR-21 transgenic hearts. Cross-
sections of hearts from 7-month-old males, wild type and miR-21,
cardiac-specific, transgenic mice, immunostained with anti-Cx43
(dark purple)
Fig. 5 ‘MiRNA erasers’ induce downregulation of endogenous
miRNA. A schematic of the miR eraser, which is a tandem repeat of
a specific miRNA antisense sequence, expressed from an RNA
polymerase III-dependent promoter such as U6. The panels below
are Northern blots of RNA extracted from cardiocytes that were
infected with 10–20 moi of the miR-21 or miR-199a erasers for 48 h
(n=3). The + sign identifies the sample lane which received the eraser
and the labels on the left define the observed signals [34]. The figure
is a reproduction from ref. [43]
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protein expressed from an RNA polymerase II-dependent
promoter, which can also be used as a reporter. The alternative
design just includes the multiple specific miRNA complimen-
tary sites flanked by stabilizing stem-loop sequences,
expressed by an RNA polymerase III-dependent promoter.
The study showed that those constructs successfully antago-
nized miRNA function in cultured cells. On the other hand,
Brown et al. used a similar design, with multiple miRNA
target sites in the 3’UTR of a transgene, for the purpose of
suppressing transgene expression in cells expressing the
corresponding miRNA [47]. In these experiments, the
authors showed that this sponge-like construct did not inhibit
the function of the endogenous miRNA. Thus, we realize that
more experiments are necessary for validating the function of
the sponges. Another aspect of this method that still remains to
be addressed, is the fate of the accumulated sponge RNA–
miRNA duplexes and their effect on cell function.
MiRNA Erasers As disclosed by the name, erasers induce
almost complete elimination of endogenous miRNA (Fig. 5)
[34]. They employ the same design concept as that of the
sponges’, which includes specific miRNA complimentary
sites expressed by an RNA polymerase III-dependent
promoter, but differ in some aspects: inclusion of only
two miRNA binding site vs. four to seven for the sponge
and the absence of the flanking stem-loops. This renders the
expressed eraser construct much shorter (40–44 nt) than the
corresponding sponge (<300 nt). In addition, the erasers
were delivered to cultured cells via recombinant adenovi-
ruses. It is conceivable that these structural differences
accounted for the mechanistic difference between the two
constructs. The erasers could be useful in generating
transgenic animal models, as a convenient alternative to
genomic knockout of miRNA. Moreover, they would provide
a solution for knocking out miRNA that exist within exons,
such as miR-21, or others that are expressed from more than
one gene. In addition, they could serve as effective tools for in
vivo therapeutic targeting of miRNA.
MiRNA replacement strategies From the abundance of
information that has been reported regarding miRNA expres-
sion patterns in various diseases, it is clear that downregulated
miRNA are represented as frequently as those upregulated.
Thus, to address their functional significance or to target
them for replacement therapy, a couple of tools have been
developed. Onewas dubbedmiRNA “mimics” or “mimetics”.
This entails delivering a duplex including the miRNA and its
compliment. This design, versus the single-stranded mature
miRNA, was necessary for efficient incorporation of the
mature miRNA into the RISC complex. The approach has
been successfully tested in cultured cells [48, 49] and the
same strategies described above for delivery of oligonucleo-
tides would apply here. Alternatively, miRNA were also
successfully expressed from their genomic or stem-loop
precursor sequence by constitutive or tissue specific pro-
moters, in tissue culture and transgenic mice models [4, 23,
34].
Exploiting Endogenous miRNA to Restrict Transgene
Expression
Tissue-targeted transgene expression is a desirable feature
for gene therapy. While this is achievable through tissue-
specific promoters, in many cases this option does not
readily lend itself, such as in undifferentiated normal or
cancerous cells. Recently, Brown et al. showed that by
introducing selective miRNA target sites into the 3’UTR of
a transgene it is possible to suppress its expression in cells
that express the corresponding miRNA [47]. As proof of
principle, the authors showed that a GFP construct contain-
ing the human embryonic stem cell (hES)-specific miR-372
target site, was only expressed during differentiated states
where miR-372 was downregulated. This could provide a
means to segregate differentiated from undifferentiated ES
cells. Similarly, one can envision a design whereby an
apoptotic gene can be delivered to a tumor, while avoiding
its expression in major organs such as the heart, brain, and
liver, by introducing the combination of miR-1, miR-124,
and miR-122 target sites in the 3’UTR of the transgene.
Concluding Remarks
Since their discovery in mammalian cells, there has been
tremendous progress in the understanding of miRNA and
their expression patterns in health and disease. As presented
above, these molecules have the potential to become more
effective therapeutic targets than single mRNA molecules.
But if we want to fully exploit them for diagnostic, prognostic,
or therapeutic purposes, we need to learn more about the
function of each individual miRNA and its range of targets.
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